Current Headlines

  1. Auckland Researchers Use Zebrafish To Screen Cancer Drugs
    7/31/2014
    A new study from the University of Auckland reports that zebrafish embryos helped researchers screen thousands of compounds to identify four new potential anti-cancer drugs.
  2. Artes And Burnet Partner In New Malaria Vaccine
    7/31/2014
    Artes Biotech and Burnet Institute have entered into collaboration to work on a new kind of malaria vaccine.
  3. NIH Awards $49M Grant To SRI For HIV/AIDS Drug Development
    7/31/2014
    SRI Biosciences announced in a press release that the National Institutes of Health (NIH) has awarded the company a seven-year grant of $49 million for HIV/AIDS drug development. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is administering the grant for preclinical development of potential therapies, including the infections prevalent in the disease. The grant also funds research for microbicides to prevent the sexual transmission of HIV.
  4. Cellectis Sells Swedish Subsidiary Cellectis AB To Takara Bio
    7/31/2014
    Cellectis announced in a press release that it has sold its Swedish subsidiary Cellectis AB to Takara Bio, a Japanese company. The sale, to be finalized soon, allows Cellectis to refocus on oncology therapies and its Chimeric Antigen Receptor T-cell (CART) immunotherapy products. Cellectis is currently partnered with Servier, Pfizer, and Accelera, a contract research organization (CRO), on CART technology. Cellectis also recently announced an agreement with European CELLforCURE to manufacture clinical batches of Cellectis’ CART cells. The sale is part of Cellectis’ restructuring effort.
  5. Otsuka, Horizon CombinatoRx Sign $835K In Vitro Cell Line Screening Deal
    7/31/2014

    Otsuka Pharmaceutical Development and Commercialization (OPDC) has inked a $846 thousand deal with Horizon CombinatoRx, a division of the UK-based business Horizon Discovery, to perform in vitro cell line screening of certain OPDC drug development candidates in 2014.

  6. ISPE Hires Healthcare Association Exec As Ceo
    7/30/2014

    ISPE—the International Society for Pharmaceutical Engineering announced today it has hired John Bournas as President and CEO, succeeding Nancy Berg who announced plans to leave the Society last fall. 

  7. Ziopharm Develops Cancer Drugs With On-Off Switch
    7/30/2014
    Biopharmaceutical firm Ziopharm Oncology announced that it has expanded its synthetic immuno-oncology programs with Intrexon Corp to develop cancer drugs that can be ‘switched’ on or off with an oral pill.
  8. J&J And Organovo Link For 3D-Printing Drug Discovery
    7/30/2014

    Johnson & Johnson company Janssen Research and Development announced that it is has entered into collaboration with bioprinting firm Organovo to investigate 3D printing of living tissue for drug discovery and research.

  9. Scientists ‘Snip’ HIV From Cultured Human Cells
    7/29/2014

    Scientists from Temple University reported that they have designed a new approach to remove HIV from human cells growing in culture through genome editing.

  10. Gilead’s Zydelig Approved By FDA For 3 Blood Cancers
    7/29/2014
    The U.S. Food and Drug Administration (FDA) announced that it has approved Gilead Sciences’ Zydelig for the treatment of three types of blood cancers.
Newsletter Signup
Newsletter Signup